EditFrom NeuroLex
Fenfluramine
| Name: | Fenfluramine |
| Description: | Fenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis. Pharmacology: Used to treat diabetes and obesity, Fenfluramine decreases caloric intake by increasing serotonin levels in the brain's synapses. Fenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes. Mechanism of action: Fenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin uptake and release of serotonin. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Drug type: Illicit. Small Molecule. Withdrawn. Drug category: Anorexigenic Agents. Serotonin Agonists. Serotonin reuptake inhibitor. Stimulants |
| Synonym(s): | DEA No, 1670, Fenfluramina (DCIT), Fenfluramine Hydrochloride, Fenfluraminum (INN-Latin), Acino, Adipomin, Obedrex, Pesos, Ponderax Pa, Ponderex, Pondimin, Rotondin |
| Related to: | 5-hydroxytryptamine 2B receptor, 5-hydroxytryptamine 2C receptor |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB00574 |
| Id: | DB00574 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about FenfluramineRDF feed
| Comment | taken from DrugBank |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB00574 + |
| Definition | Fenfluramine was withdrawn from the U.S. m … Fenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis. Pharmacology: Used to treat diabetes and obesity, Fenfluramine decreases caloric intake by increasing serotonin levels in the brain's synapses. Fenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes. Mechanism of action: Fenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin uptake and release of serotonin. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Drug type: Illicit. Small Molecule. Withdrawn. Drug category: Anorexigenic Agents. Serotonin Agonists. Serotonin reuptake inhibitor. Stimulants . Serotonin reuptake inhibitor. Stimulants |
| Has role | Drug + |
| Id | DB00574 + |
| Label | Fenfluramine + |
| ModifiedDate | 4 February 2010 + |
| RelatedTo | 5-hydroxytryptamine 2B receptor +, and 5-hydroxytryptamine 2C receptor + |
| SuperCategory | Molecule + |
| Synonym | DEA No +, 1670 +, Fenfluramina (DCIT) +, Fenfluramine Hydrochloride +, Fenfluraminum (INN-Latin) +, Acino +, Adipomin +, Obedrex +, Pesos +, Ponderax Pa +, Ponderex +, Pondimin +, and Rotondin + |